Global Idiopathic Pulmonary Fibrosis Market to grow at a CAGR of 23.97% during the period 2016-2020

ResearchMoz added Latest Research Report titled " Global Idiopathic Pulmonary Fibrosis 2016-2020 - Research and Markets " to it's Large Report database.

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

Technavios analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=717645

Covered in this report
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Read All Metabolic Disorders Market Research Reports @ http://www.researchmoz.us/metabolic-disorders-market-reports-14.html

Table of Content

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Pathogenesis
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 06: Pipeline analysis
Lebrikizumab
Tipelukast
Tralokinumab
FG-3019
Simtuzumab
BMS-986020
AF-219
SAR156597
BG00011

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG